Benzinga's Top #PreMarket Gainers

Synta Pharmaceuticals

surged 30.53% to $6.20 in the pre-market session on positive interim results from the ENCHANT-1 trial of ganetespib in metastatic breast cancer. Sinovac Biotech

shares gained 8.85% to $7.50 in the pre-market after the company reported unaudited Q4 results. Sinovac Biotech posted its quarterly net income of $5.8 million, or $0.10 per share, versus a year-ago net loss of $4.6 million, or $0.08 per share. IsoRay

surged 7.45% to $2.74 in pre-market trading as the company announced first pediatric Cesium-131 seeded mesh treatment for metastatic Wilms tumor. Novavax

shares jumped 7% to $5.50 in pre-market trading after falling 4.10% on Wednesday.